A Novel Hybrid Membrane VAD as First Step Toward Hemocompatible Blood Propulsion by Ferrari, Aldo et al.








A Novel Hybrid Membrane VAD as First Step Toward Hemocompatible
Blood Propulsion
Ferrari, Aldo ; Giampietro, Costanza ; Bachmann, Björn ; Bernardi, Laura ; Bezuidenhhout, Deon ;
Ermanni, Paolo ; Hopf, Raoul ; Kitz, Sarah ; Kress, Gerald ; Loosli, Christian ; Marina, Vita ; Meboldt,
Mirko ; Pellegrini, Giovanni ; Poulikakos, Dimos ; Rebholz, Mathias ; Schmid Daners, Marianne ;
Schmidt, Tanja ; Starck, Christoph ; Stefopoulos, Georgios ; Sündermann, Simon ; Thamsen, Bente ;
Zilla, Peter ; Potapov, Evgenij ; Falk, Volkmar ; Mazza, Edoardo
Abstract: Heart failure is a raising cause of mortality. Heart transplantation and ventricular assist device
(VAD) support represent the only available lifelines for end stage disease. In the context of donor organ
shortage, the future role of VAD as destination therapy is emerging. Yet, major drawbacks are connected
to the long-term implantation of current devices. Poor VAD hemocompatibility exposes the patient to
life-threatening events, including haemorrhagic syndromes and thrombosis. Here, we introduce a new
concept of artificial support, the Hybrid Membrane VAD, as a first-of-its-kind pump prototype enabling
physiological blood propulsion through the cyclic actuation of a hyperelastic membrane, enabling the
protection from the thrombogenic interaction between blood and the implant materials. The centre of
the luminal membrane surface displays a rationally-developed surface topography interfering with flow to
support a living endothelium. The precast cell layer survives to a range of dynamically changing pump
actuating conditions i.e., actuation frequency from 1 to 4 Hz, stroke volume from 12 to 30 mL, and
support duration up to 313 min, which are tested both in vitro and in vivo, ensuring the full retention
of tissue integrity and connectivity under challenging conditions. In summary, the presented results
constitute a proof of principle for the Hybrid Membrane VAD concept and represent the basis for its
future development towards clinical validation.
DOI: https://doi.org/10.1007/s10439-020-02590-1






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Ferrari, Aldo; Giampietro, Costanza; Bachmann, Björn; Bernardi, Laura; Bezuidenhhout, Deon; Er-
manni, Paolo; Hopf, Raoul; Kitz, Sarah; Kress, Gerald; Loosli, Christian; Marina, Vita; Meboldt, Mirko;
Pellegrini, Giovanni; Poulikakos, Dimos; Rebholz, Mathias; Schmid Daners, Marianne; Schmidt, Tanja;
Starck, Christoph; Stefopoulos, Georgios; Sündermann, Simon; Thamsen, Bente; Zilla, Peter; Potapov,
Evgenij; Falk, Volkmar; Mazza, Edoardo (2021). A Novel Hybrid Membrane VAD as First Step Toward




A Novel Hybrid Membrane VAD as First Step Toward Hemocompatible
Blood Propulsion
ALDO FERRARI,1,3,4 COSTANZA GIAMPIETRO,1,3 BJÖRN BACHMANN,1
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Abstract—Heart failure is a raising cause of mortality. Heart
transplantation and ventricular assist device (VAD) support
represent the only available lifelines for end stage disease. In
the context of donor organ shortage, the future role of VAD
as destination therapy is emerging. Yet, major drawbacks are
connected to the long-term implantation of current devices.
Poor VAD hemocompatibility exposes the patient to life-
threatening events, including haemorrhagic syndromes and
thrombosis. Here, we introduce a new concept of artificial
support, the Hybrid Membrane VAD, as a first-of-its-kind
pump prototype enabling physiological blood propulsion
through the cyclic actuation of a hyperelastic membrane,
enabling the protection from the thrombogenic interaction
between blood and the implant materials. The centre of the
luminal membrane surface displays a rationally-developed
surface topography interfering with flow to support a living
endothelium. The precast cell layer survives to a range of
dynamically changing pump actuating conditions i.e., actu-
ation frequency from 1 to 4 Hz, stroke volume from 12 to
30 mL, and support duration up to 313 min, which are tested
both in vitro and in vivo, ensuring the full retention of tissue
integrity and connectivity under challenging conditions. In
summary, the presented results constitute a proof of principle
for the Hybrid Membrane VAD concept and represent the
basis for its future development towards clinical validation.
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INTRODUCTION
Continuous flow left ventricular assist devices
(VADs) represent a routine treatment option for
patients in end stage heart failure. In the first 2 years
after implantation, the current generation of continu-
ous flow VADs achieves survival comparable to heart
transplantation.21,33 Survival and functional status are
markedly improved when compared to medical ther-
apy alone.38 On the other side, the generation of sup-
raphysiological and turbulent flow within continuous
flow VADs, and the concomitant interaction between
blood and the thrombogenic materials at the device’s
luminal interface, expose the patients to a life-long risk
of thromboembolic events and non-surgical bleed-
ing.27,37,39 At the same time, patients with continuous
flow pumps show a pathologic decrease of von Wille-
brand Factor (vWF) originating from an imbalance
between the increased degradation induced by high
wall shear stress (WSS) and the decreased endothelial
release due to the absence of pulsatility.5,7,8,31,32,40
The preservation of pulsatility represents a target of
future device development.40 Patients supported with
the CARMAT total artificial heart, a pulsatile device
partially covered with bovine pericardium at its lumi-
nal surface, showed reduced thromboembolic compli-
cations without the need for anticoagulation,
highlighting the importance of a hemocompatible
interface.17 The generation of surface textures at the
luminal interface of HeartMate XVE supported the
formation of a protective biological layer upon patient
implantation12 and reduced the risk of thromboem-
bolic events without the need of anticoagulation ther-
apy.35 However, the overall large pump size, its non-
physiological actuation and the uncontrolled genera-
tion of a biological layer represent limitations to be
addressed.
Full, long-term hemocompatibility can only be be-
stowed by the combined protection from blood surface
interactions inducing thrombosis and from blood
damage, caused by non-physiological hemodynamic
conditions created by the pump operation.
Here, we address the risk of thrombogenic events
triggered by implant materials through the generation
of a complete layer of living endothelial cells.6,23,34 In
fact, a mature endothelium at the luminal interface of
devices that are in contact with blood can provide
protection from thrombus formation and subsequent
adverse events.10
The endothelialization of blood pumps remains
however largely unexplored as a result of two inde-
pendent factors. First, the relative recent surge of
pumping devices as destination therapy. In this novel,
long-term perspective the interaction between implant
materials and blood becomes a matter of concern to-
wards the patient safety and life quality. Second, the
non-physiological hemodynamic conditions created by
the active implant, as compared to the limited inter-
ference created by passive elements such as vascular
grafts. In this sense, endothelialization technologies
applied to VADs face completely new challenges,
which include the formation and/or maintenance of a
connected tissue under supraphysiological combina-
tions of WSS and wall deformation (WD).4 As most
VAD-associated thrombotic events are registered
during the first years of support an immediate pro-
tection must be considered. For this reason, the in vitro
generation of a mature endothelial monolayer prior to
device implantation must be preferred to ensure the
luminal sheltering during the early phases of device
actuation.
The actuation of blood pumps yields complex and
dynamic gradients of flow-generated WSS which is
accompanied by local strain (i.e., WD) when deform-
able elements are part of the actuation scheme.14 In
particular, the luminal surface of current VAD features
regions of perturbed hemodynamic loads, which prove
non-viable for endothelial cells.1,36 This scenario
requires a novel concept to be developed which shall
include two converging approaches: (i) The establish-
ment of an alternative pump design, engineered to
support a failing heart while minimizing the hemody-
namic load and therefore rendering a viable substrate
for endothelialization2 and, (ii) The implementation of
engineered luminal substrates, extending the survival
of endothelial cells under highly dynamic and turbu-
lent flow conditions.4
Here, we describe the development and validation
(in vitro and in vivo) of a novel pump concept (the
Hybrid Membrane VAD; HyMem-VAD) fulfilling the
above design criteria. The primary objectives of the
presented acute animal study were (i) the development
and clinical adaptation of an endothelialization pro-
tocol, (ii) the test of safety and actuation performance
for the HyMem-VAD, and (iii) the endpoint analysis




The hybrid membrane was generated by molding
the hyperelastic RTV 4420 silicone11 into an elliptic
layer. The chosen design parameters included an aspect
ratio of 2:1 and length of the major radius of 44 mm.
The membrane features a pattern of corrugations in
the cross section protruding along the minor axis





FIGURE 1. Hybrid Membrane VAD design. (a) The left-hand side shows the full pump assembly, including polymer valves (light
blue) and the hybrid membrane (yellow). The right-hand side shows a close up section of the corrugated membrane. Red marks the
endothelialized region, which contains the hexagonal surface topography (shown in SEM close-up). Panel (b): The parameterized
design of molding tools and the resulting RTV polymer valve are shown on the left-hand side. On the right-hand side a TAVI valve
(by SAT) is shown. Panel (c) shows the set-up of the long term test bench. The VAD is connected to vertical pressure cylinders with
compliant silicone tubing. A magnification of the pump can be seen in panel (d). This version of the pump is fitted with additional
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the extent of WD generated on the surface upon full
membrane extrusion.19 In addition, the corrugations
are tapered along the major axis to minimize their
interference with flow. Upon actuation, the central
region of the membrane is cyclically exposed to high
levels of WSS (up to 15 Pa) and WD (up to 16% areal
strain range), see Refs. 18 and 20. This demanding
interface was therefore selected as benchmark to test
endothelialization performance. Here, to locally sup-
port the adhesion of endothelial cells and the forma-
tion and maintenance of a connected endothelial
monolayer, honeycomb hexagonal wells with opti-
mized size and geometry (well basal sur-
face = 1045 lm2, well height = 6 lm, wall
width = 4 lm) were implemented upon membrane
fabrication (Fig. 1a4). Extended description is pro-
vided as supplementary information.
Pump Design
The HyMem-VAD is a pulsatile, volume displace-
ment pump with design and operation features en-
abling actuation at high pulsation rates and thus
minimizing the overall device volume. The technolog-
ical core of the pumping scheme is represented by a
hyperelastic silicone membrane which is cyclically
actuated. The membrane features a pattern of luminal
corrugations designed to mitigate the levels of tensile
strain upon its full extension. Importantly, the pump
design, operation and dedicated topographical pat-
terning4 enable luminal endothelialization. We de-
scribed the most relevant aspects of the in vitro pump
development.3,11,24,29,36
Specifically, the pump structure comprises two
superimposed chambers horizontally separated by the
hybrid membrane (Figs. 1a, 1d). Blood flows in the
upper chamber (the blood chamber) while a physio-
logic saline solution is injected into the lower chamber
(actuation chamber). The flow directionality is im-
posed by one-way valves at the inlet and outlet of the
blood chamber (Fig. 1a). In the actuation scheme, a
cyclic volume exchange in the actuation chamber in-
duces the controlled extrusion of the hybrid mem-
brane, thus enabling blood propulsion. The hybrid
membrane represents therefore the core technological
element of this scheme. Extended description of the
hybrid membrane fabrication is provided in ‘‘Materials
and Methods’’ section.
The pump dimensions were set to yield at a maxi-
mum output of 5 l/min while maintaining the apex
strain (i.e., at the central region) on the hybrid mem-
brane below 6%. To reduce the necessary stroke vol-
ume (SV) and the resulting overall pump size, the
operating frequency was raised to 240 bpm (4 Hz29).
The prototype features in- and outlet polymeric tran-
scatheter valves (Figs. 1a and 1b). Two different valve
types were tested: a TAVI valve (Strait Access Tech-
nologies, SAT, Cape Town, South Africa) and a cus-
tom-developed polymeric tri-leaflet valve (Fig. 1b),
made from same silicone elastomer as the propulsion
membrane and the coating of the housing (i.e., RTV
4420). The TAVI prosthesis consists of three poly-
urethane based leaflets, which are connected to a
stainless steel stent. The custom made RTV valves were
realized based on iterative design and manufactured
using a 3D printed negative mold. Finally, the diam-
eter of the chosen cannulae is 20 mm to mitigate WSS
by reducing the resulting flow speeds.
Computational Studies
To evaluate the mechanical and fluid-dynamic loads
generated by the pump actuation on the luminal sur-
face of the hybrid membrane, a finite-element and a
computational fluid dynamic (CFD) models were
developed. The finite-element model rendered the ex-
pected membrane deformation, which constituted the
input for CFD. This analysis did not consider fluid–
structure interactions as for the present hemodynamic
conditions no relevant coupling is expected.
The flow conditions in the pump were analyzed for
different operating conditions in Refs. 18 and 20 and
compared with those of a conventional circularly
shaped pump chamber indicating improved conditions
of WSS for the present elliptical design. Figure 2 shows
examples of streamlines obtained from the integration
of the corresponding velocity fields during the diastolic
phase. For the present study, the analysis of simula-
tion’s results focused on ellipsoidal area with radius of
5 mm, located at the center of the hybrid membrane
(Fig. 1).
The numerical analysis was applied to estimate
mechanical strain and fluid stress during pump oper-
ation.20 Particle tracking velocimetry (PTV) measure-
ments were performed to validate the predicted
velocity fields (Fig. 3) as previously reported.18–20
The WSS at the contacting surface was investigated
by performing a non-steady state CFD study of the
pump at two operation frequencies of 120 bpm and
240 bpm with a stroke volume of 30 mL.20 The results
of these calculations, along with those of correspond-
ing finite element simulations of the membrane defor-
mation (see Supplementary Methods) were used to
select the portion of the membrane to be covered with
endothelial cells. The initial membrane shape was
assumed to be flat in order to reduce the complexity of
the CFD model. The membrane motion was imple-
mented as a moving boundary into the finite-volume





18.2 User’s Guide.’’ 2017). Extended description is
provided as supplementary information.
Long-Term In Vitro Testing
The long term, cyclic behavior of the hybrid mem-
brane was investigated using a custom-developed long
term test bench (Figs. 1c and 1d). This test bench was
designed to operate the pump at different actuation
frequencies and SV under physiological pressure con-
ditions. Various studies were performed with the whole
pump exposed to a range of realistic operating condi-
tions. It could be shown that a long term actuation
does not impair the mechanical integrity of the silicone
membrane. At 3 L/min pumping rate (realized at 4 Hz
actuation frequency and 12.5 mL SV), over 25 million
cycles were achieved over a period of 2.5 months.
Subsequently, the membrane was retrieved from the
pump and visually inspected. No crack initiation sites
could be found and also no zones of macroscopic
plastic deformation could be identified. The endurance
demonstrated in this test is in line with previous
investigations on the cyclic behavior of the RTV 4420
silicone used for the hybrid membrane.11,14 These test
results helped defining a safe-range for the actuation
settings which were later used in the animal experi-
ments. In order to demonstrate adequate endurance
for clinical use, future investigations will involve long
term tests with several hundred millions of cycles.
Cell Culture
Adult ovine endothelial cells (ECs) were harvested
from fresh saphenous vein biopsies (Figs. 4a and 4b).
They were grown in medium 200PRF
(#M200PRF500, ThermoFisher Scientific) containing
LSGS Kit (#S-003-K, ThermoFisher Scientific). The
kit includes fetal bovine serum (FBS) 2% v/v;
hydrocortisone (1 lg/mL); human epidermal growth
factor (10 ng/mL); basic fibroblast growth factor
(3 ng/mL) and heparin (10 lg/mL). Cells were
maintained at 37 C and 5% CO2. All reported
in vivo experiments were performed using cells with
less than 5 passages in vitro. Cells were tested for
their ability to reconstitute a mature, growth-arrested
endothelial monolayer on a synthetic surface. For
this analysis, the target substrate was coated with
cross-linked gelatin.16 Cells were seeded at high initial
density (105 cell/cm2).
Tissue generation was assessed after 3 days,
through immunofluorescence analysis for endothelial
junctional complexes, including VE-cadherin and b-
catenin, major components of adherens junctions
(AJs9), and ZO-1, major component of the tight
junctions (TJs9). The distribution of cell-to-cell
junctions confirmed the generation of fully mature
and connected endothelium on target substrates
(Fig. 4c). Extended description is provided as sup-
plementary information.
FIGURE 2. Illustration of the flow field: at the beginning (a and b) and at an intermediate state (c and d) of the diastolic phase. The
images show the streamlines (a and c) for selected points at the inlet of the pump obtained from an integration of the
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Antibodies
The following primary antibodies were used: goat
polyclonal anti-VE-cadherin (1:200, sc-6458, Santa
Cruz Biotechnology Inc.), mouse monoclonal anti-b-
catenin (1:100, #610154, BD Biosciences), mouse
monoclonal ZO-1 Alexa Fluor 555 (1:100, 1A12,
ThermoFisher Scientific). F-actin was stained with
TRIC-Phalloidin (SIGMA ALDRICH, P1951). Sec-
ondary antibodies were donkey anti-goat–Alexa 488
(A11055, Invitrogen), chicken anti-mouse-Alexa 647
(A21463, Invitrogen).
Microscopy and Image Processing
Fluorescent images of immunostained samples were
acquired with a 9 40, 1.3 NA oil immersion objective
(Plan Fluor, Nikon, Japan), using a FITC filter, a
TRITC filter, a Cy5 filter and a DAPI filter for the cell
nuclei. Only adjustment of brightness and contrast
were used in the preparation of the figures. For com-
parison purposes, different sample images of the same
antigen were acquired under the same microscopy
acquisition settings.
FIGURE 3. First Principal Elastic Strain and Wall Shear Stress at the cell contacting surface over one pump cycle for a pump
frequency of 120 and 240 bpm. Time 0 corresponds to the beginning of the diastole. Sections of the vector-fields from PTV
measurements are visualized above (corresponding to 120 bpm) and below (corresponding to 240 bpm). The color-bar






All experimental protocols were approved by the
Landesamt für Gesundheit und Soziales Berlin (La-
GeSo, G 205/17), the local German authorities
(Number G 0215/17). All methods were carried out in
accordance with relevant guidelines and regulations.
The actuation side of the pump housing was con-
nected via a hydraulic tube to a PTFE bellows (El-
ringKlinger AG, Dettingen/Erms, Germany), which in
FIGURE 4. Isolation and characterization of ovine ECs. (a) Representation of the ovine Saphenous vein and (b) bright field image
of a typical endothelial monolayer. Scale bar: 100 lm. (c) VE-cadherin, b-catenin and ZO-1 immunostaining of endothelial
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turn was connected to a voice coil (lvcm-095-089-01,
Moticont, Van Nuys, CA, USA) that compresses and
stretches the bellows. Figure 8 shows a schematic of
the actuator. An air bearing (S301301, Newway Air
Bearings, Aston, PA, USA) kept the movement of the
bellows and voice coil frictionless. As hydraulic fluid a
saline solution was used which can be assumed to be
incompressible. The stiff hydraulic line additionally
allowed neglecting differences in displaced volume
between bellows and membrane. The displacement
volume of the membrane therefore could be directly
correlated to the displacement of the bellows. For the
trial the bellows and therefore the membrane were
displaced in a sinusoidal way. The actuation parame-
ters, the stroke volume and frequency together with
their respective application times are shown in Table 1.
By that, the cells were exposed to a broad range of
operating points that covers the majority of flow con-
ditions seen in patient application. These experimental
conditions were selected for two main purposes: (i) to
evaluate endothelial integrity over a wide range of
pump operation states and (ii) to verify that the pump
can be stably controlled over a wide range of operating
conditions. The actuation sequence was selected to
create rapid variations of local hemodynamic loads at
the luminal surface of the hybrid membrane, therefore
challenging the survival of endothelial cells. Extended
description is provided as Supplementary Information.
Sensors
During the trial, the displacement of the membrane
was measured by the bellow displacement with a laser
sensor (OptoNCDT 1320, Micro-Epsilon Messtechnik
GmbH & Co. KG, Ortenburg, Germany) with a
sample frequency of 2 kHz. The blood flow through
the pump was measured by an ultrasonic flow sensor
(SONOFLOW CO.55, SONOTEC Ultraschallsensorik
Halle GmbH, Halle, Germany) placed around the
outlet graft. Left ventricular, arterial and central ve-
nous pressure were recorded through TruWave pres-
sure sensors (Edwards Lifesciences Corp., Irvine,
USA). All data was sampled through a MF634
Humusoft Data Acquisition card (Humusoft s.r.o,
Prague, Czech Republic) with a sampling frequency of
100 Hz. The data acquisition was running simultane-
ously to the actuation control on a Real-Time Win-
dows Target environment in MATLAB/Simulink
(MathWorks, Inc., Natick, MA, USA).
Statistical Analysis
Statistical comparison of cell density was performed
using a t test. The Shapiro–Wilk test was used to test
for normality of data with a significance level of 0.05.
The p-values reported in Fig. 5 are obtained by com-
paring several individual measures of cell density
obtained in different fields of view for each individual
sample. The resulting measure of density variation
across the endothelial monolayer is relevant, as the
initial phases of denudation (reporting on the failure of
the endothelialization strategy and the maintenance of
a fully confluent protection) appear with local, re-
stricted loss of cell coverage.
RESULTS
In Vitro Endothelialization
The in vitro test bench was initially exploited to
evaluate the performance of the proposed endothe-
lialization approach. The conditions of pump actua-
tion for these preparatory experiments fully
reproduced those envisioned for the animal tests.20 The
TABLE 1. Overview of pump actuation parameters and their respective application durations
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central region of the hybrid membrane, featuring
honeycomb hexagonal wells (Fig. 1a), was previously
coated and seeded with ovine ECs. The selected
topographical features support endothelial cell reten-
tion without compromising monolayer integrity.4 The
effect is obtained through a mitigation of the apparent
WSS at the apical side of ECs nested in the hexagonal
wells, as previously demonstrated by in vitro tests un-
FIGURE 5. Analysis of endothelialization. In vitro test bench: (a) immunofluorescence analysis for actin (red) and VE-cadherin
(green). Nuclei are stained with DAPI (blue). Scale bar: 100 lm; (b) SEM analysis of endothelialized hexagonal topography, scale
bar: 100 lm, and (c) quantification of the cell density; no statistical significance: 2 Hz vs. static p = 0.4, 4 Hz vs. static p = 0.2. In
vivo trials: (d) immunofluorescence analysis for actin (red) and b-catenin (green). Nuclei are stained with DAPI (blue). Scale bar:
100 lm, (e) quantification of the cell density; no statistical significance. Animal 1 vs. static p = 0.6, Animal 3 vs. static p = 0.4,
Animal 4 vs. static p = 0.7. Static samples were obtained maintaining the fully mounted device in static conditions in an incubator.
These membranes did not undergo the process of implantation. On the other hand, the sample denoted as ‘no actuation’ (Animal 1)
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der a range of supraphysiological actuating condi-
tions.4 In these tests, the topographically-modified
surfaces were compared to an equivalent substrate
featuring a completely flat surface and demonstrated a
superior maintenance of monolayer integrity upon
exposure to supraphysiological hemodynamic condi-
tions of combined WSS and WD.4
After 3 days of incubation in static conditions, the
endothelialized membrane was mounted in the hybrid
membrane pump. During the entire procedure the
luminal surface was maintained in contact with culture
medium and care was taken to avoid bubbles. The
prototype was then plugged to the test bench (Fig. 1c)
and actuated while the entire device was maintained in
an incubated environment. Specifically, the system was
subjected to cyclic actuation at 2 or 4 Hz, yielding an
average output of 2.5 L/min and 4.0 L/min, respec-
tively. Cell survival and endothelialization perfor-
mance were assessed through an endpoint
immunostaining analysis for junctional proteins and
actin cytoskeleton (Fig. 5a). Under all tested condi-
tions, the luminal endothelium remained intact.
Endothelial cell-to-cell junctions displayed the typical
linear morphology along the boundaries between
adjacent cells22 and were in contact with cortical F-
actin. Importantly, the cell morphology adapted to the
underlying hexagonal topography, as previously
reported (Fig. 5b4). The resulting local cell density was
comparable to the control (an identical membrane
maintained in static conditions, Fig. 5c). In all, these
results demonstrate that the endothelialization proto-
col and the actuation conditions within the HyMem-
VAD (see Materials and Methods) are viable and allow
for the generation and maintenance of a connected
endothelial monolayer. These achievements repre-
sented the prerequisite required to advance the
endothelialization protocols to their application in
animal trials.
In Vivo Actuation
All experimental animals (Animal #1–4) were sub-
jected to full implantation of the HyMem-VAD
(Fig. 6). A complete description of the surgical settings
is provided in Supplementary Materials and Methods.
All trials were completed successfully. They allowed
for the evaluation of the endothelialization procedure
and of different actuation schemes, as previously tested
in vitro (Figs. 4, 5, 6, 7, and 8).
Specifically, in Animal #1 the pump was endothe-
lialized but not actuated representing therefore a pas-
sive element in the circulation. This first test was
necessary as internal control for the viability of the
endothelialization and mounting procedures, as well as
to assess the interaction between cells and blood.
Animal #2 served instead as control to minimize the
risk of cell damage during the procedure of pump
deployment, blood filling, connection with sensors and
control system and initial actuation. The second main
objective of this experiment was to evaluate the effec-
tiveness of the control system of the pump in vivo. To
this end, the animal physiological parameters (arterial
blood pressure, oxygenation level and heart rate) were
monitored for different pump actuation conditions and
for the transient states between them. This allowed to
verify that the interaction of our pump with the native
organ was not causing detrimental effects at the given
set-points and during the transition from an operating
condition to the next one. The results were used to
optimize the experimental procedures and the
endothelialization approach in the ensuing animals. In
Animals #3 and 4 the HyMem-VAD was endothelial-
FIGURE 6. Experimental configuration of in vivo trials. Left: schematic representation of the pump configuration including pump
housing with polymer valves at in- and outlet position. The inlet of the device is connected to the apex of the left ventricle. The graft
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FIGURE 7. Prevailing pressures and flows during pump operation. The top panels of (a) and (b) show the arterial blood pressure
(ABP), left ventricular pressure (LVP) and central venous pressure (CVP) of animal 3 and 4, respectively. The bottom panels of (a)
and (b) show the blood flow through the pump (Qpump) and total cardiac output (QtCO) consisting of blood flow through the pump
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ized and actuated, therefore representing the full
experimental result of the in vivo tests. Complete de-
tails on the actuation parameters in these animals are
provided in Table 1.
End-Point Analysis
At the end of each experiment, the HyMem-VAD
was cross clamped and carefully removed from the
animal body. The actuation lid and the hybrid mem-
brane were dismounted and carefully rinsed with warm
medium to clear the surface from blood and preserve
the sample. The membranes were then immediately
fixed.
To evaluate the performance of the endothelializa-
tion procedure and thus the maintenance of a con-
nected endothelial tissue, the fixed specimens were
immunostained to reveal the cell nuclei, the actin
cytoskeleton and the cell-to-cell junctions (with b-ca-
tenin; Fig. 5). All tested experimental configurations
(i.e., no actuation, actuation at 2 or 4 Hz) proved vi-
able for ECs. In fact, the retrieved endothelia were
completely intact, ensuring a full coverage of the target
substrate with no visible discontinuity. The junctional
localization of b-catenin confirmed full integrity of the
monolayer, which was in all comparable to those
obtained in control static conditions (Fig. 5d). Quan-
titative measurements further showed no significant
changes in local cell density upon implant deployment
(Fig. 5e).
DISCUSSION
The presented study demonstrates that the HyMem-
VAD implantation protocol and actuation schemes are
conducive to device endothelialization, preserving a
living endothelium for the entire test duration. Addi-
tionally, the endothelialization procedure was suc-
cessfully adapted to the clinical settings. Altogether,
the results demonstrate the feasibility of the innovative
concept and represent the necessary basis for its further
development. Future validation and translational work
will require to secure a complete protection to the
implant materials getting in contact with blood. For
this to be achieved, we envision a fabrication process
that implements the selected topography on the entire
luminal surface. The procedure shall be applied to
multiple non-planar material interfaces (elastomers,
metals, and plastic polymers) therefore requiring
optimization of the fabrication protocol. This addi-
tional effort will base on the feasibility study presented
and will establish the all-round technology for pre-
clinical tests, which shall be performed with a fully
FIGURE 8. Schematic of pump actuation unit consisting of the HyMem-VAD at the top, a hydraulic line connecting the HyMem-





protected device and tubing. In fact, any bare surface
in contact with blood would represent a site for the
initiation of thrombotic events, therefore posing a
threat to the success of the entire new concept.
The Hyperelastic Membrane Design and Validation
The hyperelastic membrane represents the techno-
logical core of the HyMem-VAD concept (Fig. 1). The
design allows a cyclic membrane actuation up to 4 Hz
while avoiding the generation of excessive strains at the
luminal surface (Figs. 2 and 3). This results in pumping
rate of up to 5 L/min and qualifies the HyMem-VAD
as potential support for end stage heart failure
patients13,15 and device endothelialization (Fig. 7). The
choice of operation at 4 Hz is a limitation of the cur-
rent design, which however allows the containment of
the overall pump dimensions. The aortic pulsatility
was not in the scope of this study and no sensor was
placed in the vicinity of the aorta. Two separate studies
have investigated pulsatile VADs operated at fre-
quencies that exceed the heart rate.29,30 The in silico
and in vitro results demonstrated that pulsatility re-
mains sufficiently high despite the high frequency of
operation. In all, the present work is a unique example
of a converging approach in which engineering and
biological requirements are considered together during
the design phase. It demonstrates that physiologically-
relevant actuation and device endothelialization are
possible and compatible in a heart failure support de-
vice (Fig. 8).
The current pump design and overall size are opti-
mized towards its intended experimental use and not to
achieve implantability. The prototype features a large
flange, clamping rings and screw connections to clamp
the two halves of the pump housing to facilitate
mounting and demounting of membranes and valves.
Additionally, the cannulas are designed for extracor-
poreal animal experiments and specifically to visually
assess the state of the pump. For this purpose the
outlet cannula features a big curvature as shown in
Fig. 1.
Future development for clinical translation will
consider a more compact design. In particular, for a
clinically-optimized prototype such design elements
(flange, clamping rings and screw connections) will be
eliminated and the residual volume conformed by the
actuation. The blood chamber with connections for the
cannulas will be similarly reduced in size. In parallel,
we envision a new design of the cannulas and pump
body to achieve an implantation configuration with
curved inlet cannula and straight outlet. The reduction
of the pump size through the incorporation of
increased stroke frequencies is instrumental in this
approach.
The In Vitro Endothelialization Approach
The endothelialization of artificial substrates has
been applied to attain in vivo protection of vascular
grafts.6 In this case, successful coverage was based on
the in vitro generation of a precast autologous
endothelium.41 Alternatively, porous materials have
been applied to foster efficient transmural ingrowth.26
More recently, attempts to extend this procedure to
vascular stents exploited the in vivo regenerative
potential of circulating endothelial precursors, locally
recruited to the luminal interface.25,28 VAD endothe-
lialization involves tissue generation and maintenance
under complex flow conditions36 which can be locally
mitigated by the implementation of surface topogra-
phies interfering with flow.4
The here-reported tests demonstrate that a ration-
ally-designed honeycomb topography (Fig. 1) can
support the generation and maintenance of a fully-
connected and functional endothelium (Figs. 4 and 5)
in representative regions of the HyMem-VAD featur-
ing a dynamically changing hemodynamic land-
scape.18,20 The same fabrication approach can be
extended to other regions of the system. In addition,
the precast endothelium was generated using cells
isolated from the Vena Saphena, which represents a
potential source of endothelialization for cardiovas-
cular devices in human patients. Based on these con-
siderations, the endothelialization protocol can
theoretically be upscaled to cover the entire luminal
surface of the HyMem-VAD.
From the biological point of view, we have obtained
a sound proof that the chosen materials, the selected
interface topography, the endothelialization protocols,
the implantation procedure, and the actuation in vivo
are all compatible with the survival of a reconstituted
endothelium. Endothelial cells and tissues are very
delicate and would immediately suffer from non-viable
conditions. Therefore, the maintenance of tissue in-
tegrity after several hours of actuation is a non-trivial
technical challenge and undoubtedly provides a proof
of viability on which we can leverage for our future
developments. Altogether, these results demonstrate
that the HyMem-VAD is compatible with device
endothelialization based on the in vitro generation of a
precast endothelium. Alternative endothelialization
mechanisms, including the contribution of circulating
endothelial precursors, may play an additional sup-
portive role.
The response of the endothelium, and of the entire
cardiovascular system, upon exposure to high fre-
quency pulsations for extended periods of time will be
addressed by the future development of our novel
concept. This investigation shall be pursued by means
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term actuation of the HyMem-VAD, and chronic
animal studies. Altogether, these future efforts shall
provide a clear evaluation of the proposed trade-off
between low WSS and high actuation frequency.
Limitations
The present study has several limitations. All
reported results were obtained in acute in vivo tests
during which the animals were constantly under full
anesthesia. Therefore, our conclusions are restricted
to the validation of the clinical procedure for pump
endothelialization, assembly, implantation and initial
actuation. Further chronic experiments will be nec-
essary to evaluate the survival of the endothelium and
its long-term adaptation to the pump function in vivo.
In addition, the extended time necessary for the
preparation and implantation of the pump system
contributed to define, and limit, the duration of the
actuation phase. The limited time window during
which the experimental animals showed stable physi-
ological parameters defined the duration of the actual
experiments. The luminal endothelialization of the
HyMem-VAD was restricted to a central portion of
the hyperelastic hybrid membrane. This was selected
due to the prevailing values of hemodynamic stresses
to which cells are exposed during pump actuation.
While 5 L/min are considered a relevant level of
support for clinical application, extension to 8–10 L/
min flow represent a desirable feature for a wider
applicability of the heart pump. Correspondingly, our
future experiments will investigate the feasibility of
device actuation and cell viability under increased
level of flow.
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